The Relationship of HER2 Copy Number Evaluated by Brightfield Dual In Situ Hybridisation DNA Assay and Pathologic Response to Neoadjuvant Treatment in HER2 Positive Breast Cancer

被引：0
|
作者：
Neville, G. [1 ]
Feeley, L. [1 ]
Bennett, M. W. [1 ]
O'Reilly, S. [1 ]
Corrigan, M. [1 ]
O'Connell, F. [1 ]
Browne, T. J. [1 ]
机构：
[1] Cork Univ Hosp, Cork, Ireland
来源：
JOURNAL OF PATHOLOGY | 2017年 / 243卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 50 条
  • [41] Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
    Guarneri, V.
    Barbieri, E.
    Dieci, M. V.
    Piacentini, F.
    Conte, P.
    CANCER TREATMENT REVIEWS, 2010, 36 : S62 - S66
  • [42] Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
    Li, Xiaoxian
    Zhao, Jing
    Zhang, Chao
    Li, Zaibo
    MODERN PATHOLOGY, 2019, 32
  • [43] Genomic and clinical characterization of breast tumors with unusual HER2 FISH pattern (ratio < 2, HER2 copy number ≥ 6): Are they mostly HER2 "positive?"
    Wei, Christina H.
    Yang, Lixin
    Stewart, Daphne
    Bedell, Victoria
    Schmolze, Daniel
    Apple, Sophia
    Murata-Collins, Joyce L.
    Pillai, Raju
    Mortimer, Joanne E.
    CANCER RESEARCH, 2022, 82 (04)
  • [44] Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer response
    Brede-Hekimian, Katya
    LANCET, 2012, 379 (9833): : 2237 - 2237
  • [45] Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
    Chen, Hai-Long
    Chen, Qiang
    Deng, Yong-Chuan
    MEDICINE, 2021, 100 (44)
  • [46] Loss of HER2 amplification and disease prognosis after neoadjuvant treatment of HER2 amplified breast cancer
    Paralta Branco, F.
    Silva, F.
    Andre, S.
    Catarino, A.
    Madureira, R.
    Moreira Pinto, J.
    Godinho, J.
    Simoes, P.
    Freitas, A. C.
    Casa-Nova, M.
    Nave, M.
    Augusto, J.
    Passos-Coelho, J. L.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S94 - S94
  • [47] HER2 status in breast cancer patients: A comparison between borderline positive HER2 and strongly positive HER2 tumors
    Huszno, J.
    Nowara, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S137 - S137
  • [48] Is HER2 loss after neoadjuvant chemotherapy determinant for the choice of adjuvant treatment in HER2 positive breast cancer patients? Reply
    Yoshida, Atsushi
    Hayashi, Naoki
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (02) : 329 - 329
  • [49] HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
    Novillo, Apolonia
    Gaibar, Maria
    Romero-Lorca, Alicia
    Malon, Diego
    Anton, Beatriz
    Moreno, Amalia
    Fernandez-Santander, Ana
    CANCERS, 2023, 15 (03)
  • [50] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Sumanpreet Kaur
    Rajasri Bhattacharyya
    Dibyajyoti Banerjee
    Jaya Shukla
    Indian Journal of Clinical Biochemistry, 2021, 36 : 124 - 125
12345